Evidence map›Paper›PMID 28694183›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity.

Evelyn C Nieves, Tomomi Toubai, Daniel C Peltier, Katherine Oravecz-Wilson, Chen Liu, Hiroya Tamaki, Yaping Sun, Pavan Reddy

Abstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Evelyn C NievesDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
Tomomi ToubaiDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
Daniel C PeltierDivision of Hematology and Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.
Katherine Oravecz-WilsonDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
Chen LiuDepartment of Pathology and Laboratory Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Hiroya TamakiDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Yaping SunDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
Pavan ReddyDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan. Electronic address: reddypr@med.umich.edu.

Funding

Training Program in Molecular HematologyT32HL007622 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SUNG WON CHOI, Jordan A. Shavit · 1986 to 2026
$9.2M
Targeting antigen presentation to enhance GVL responses after Bone Marrow TransplR01HL090775 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2008 to 2016
$3.4M
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severityR01CA203542 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2016 to 2020
$2.4M
Development of novel strategy for treatment of steroid refractory GVHDR01HL128046 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2015 to 2019
$2.1M
Role of noncoding RNA in Regulating GVHDR01CA173878 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA173878NCI NIH HHS R01 CA203542NHLBI NIH HHS R01 HL090775NHLBI NIH HHS R01 HL128046NHLBI NIH HHS T32 HL007622
6 · The paper itself

Abstract

Professional antigen-presenting cells (APCs) are important modulators of acute graft-versus-host disease (GVHD). Although dendritic cells (DCs) are the most potent APC subset, other myeloid cells, especially macrophages (MFs) and neutrophils, recently have been shown to play a role in the severity of GVHD. The critical molecular mechanisms that determine the functions of myeloid cells in GVHD are unclear, however. Signal transducer and activator of transcription 3 (STAT3) is a master transcription factor that plays a crucial role in regulating immunity, but its role in MF biology and in acute GVHD remains unknown. To determine the impact of myeloid cell-specific expression of STAT3 on the severity of acute GVHD, we used myeloid cell-specific STAT3-deficient LysM-Cre/STAT3

Indexed as

AnimalsGraft vs Host DiseaseMiceMice, Inbred BALB CMyeloid CellsSTAT3 Transcription FactorTransplantation, HomologousTransplant RecipientsStat3 protein, mouseSTAT3 Transcription FactorBone marrow transplantationGraft-versus-host diseaseMyeloid cellsSTAT-3

Identifiers

PMID28694183
PMCPMC6088768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.